Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagno... (rates of severe or fatal hemorrhage amon...)

HOME >> BIOLOGY >> TECHNOLOGY

Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests

Date:6/11/2008

rates of severe or fatal hemorrhage among patients

with squamous NSCLC histology compared with non-squamous NSCLC. In

addition, several other targeted drugs for NSCLC currently under

development may require this sensitive differentiation.

- Mesothelioma vs. Adenocarcinoma - Differentiating between mesothelioma

and adenocarcinoma is critical for optimal therapy, but it is often

difficult to differentiate. Currently, there is no objective,

standardized test to aid pathologists in differentiating between the

many possible tumors in the lung and pleura. Based on several microRNA

biomarkers, this test is designed to separate mesothelioma from

adenocarcinoma tumors including lung adenocarcinoma and metastases to

the lung or to the pleura

- Cancer of Unknown Primary (CUP) - In 3%-5% of all new cancer patients,

clinicians cannot identify the origin of a patients' tumor. This

information is crucial for determining treatment type.

As demonstrated in a paper published by Rosetta Genomics and collaborators in the April issue of Nature Biotechnology, Rosetta Genomics has developed a panel of microRNA biomarkers potentially able to identify approximately thirty cancer types. This test is designed to assist clinicians to accurately identify the origin of tumors.

About MicroRNA

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

Abo
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. /C O R R E C T I O N -- Rosetta Genomics Ltd/
2. Rosetta Genomics Reports First Quarter 2008 Financial Results
3. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
4. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
5. Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference
6. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
7. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
8. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
9. Rosetta Genomics Establishes Medical Advisory Board
10. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
11. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008

Post Your Comments:

Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagno...(rates of severe or fatal hemorrhage amon...)